Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-3-pyridinyl)methoxy)benzaldehyde
2. Gbt440
3. Oxbryta
1. 1446321-46-5
2. Oxbryta
3. Gbt440
4. Gbt 440
5. Gbt-440
6. Gtx-011
7. Hemoglobin Modulators-1
8. Voxelotor [usan]
9. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
10. 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
11. Chembl4101807
12. 3zo554a4q8
13. Voxelotor (usan)
14. 2-hydroxy-6-({2-[1-(propan-2-yl)-1h-pyrazol-5-yl]pyridin-3-yl}methoxy)benzaldehyde
15. Benzaldehyde, 2-hydroxy-6-((2-(1-(1-methylethyl)-1h-pyrazol-5-yl)-3-pyridinyl)methoxy)-
16. 2-hydroxy-6-((2-(1-(propan-2-yl)-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
17. Oxbryta (tn)
18. Voxelotor [inn]
19. Gbt-440(voxelotor)
20. Voxelotor [mi]
21. Voxelotor [who-dd]
22. Unii-3zo554a4q8
23. Voxelotor [orange Book]
24. Schembl15065529
25. Gtpl10559
26. Voxelotor(gbt440, Gtx011)
27. Dtxsid801027954
28. Bcp20182
29. Ex-a2980
30. Bdbm50235297
31. Zinc145969085
32. Ccg-267884
33. Cs-5317
34. Db14975
35. Sb19656
36. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-3-pyridinyl)methoxy)benzaldehyde
37. Compound 36 [pmid: 28337324]
38. Ac-36867
39. As-57911
40. Da-44587
41. Hy-18681
42. Ft-0702904
43. S8540
44. D11330
45. Gbt-440;gbt440;voxelotor;gtx-011;gtx011;gtx 011
46. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy) Benzaldehyde
Molecular Weight | 337.4 g/mol |
---|---|
Molecular Formula | C19H19N3O3 |
XLogP3 | 2.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 337.14264148 g/mol |
Monoisotopic Mass | 337.14264148 g/mol |
Topological Polar Surface Area | 77.2 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 434 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Voxelotor is indicated to treat sickle cell disease in both adult and pediatric patients aged 4 years and older.
Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
Voxelotor modifies hemoglobin to prevent painful and dangerous sickle cell crises that normally lead to organ damage, hospitalization, and sometimes death. It prevents low hemoglobin, which is normally associated with the destruction of sickled blood cells in sickle cell disease. Voxelotor has led to up to a 40% increase in hemoglobin in clinical trials.
Hematologic Agents
Drugs that act on blood and blood-forming organs and those that affect the hemostatic system. (See all compounds classified as Hematologic Agents.)
B06AX03
B - Blood and blood forming organs
B06 - Other hematological agents
B06A - Other hematological agents
B06AX - Other hematological agents
B06AX03 - Voxelotor
Absorption
Voxelotor is rapidly absorbed after oral administration, with a plasma Tmax of 2 hours. Tmax in the red blood cells ranges from 17-24 hours. The Cmax, on average in whole blood and red blood cells occur 6 and 18 hours after an oral dose, respectively. Consumption of a high fat meal with voxelotor significantly increased exposure to the drug during clinical trials. After a daily dose of either 300, 600, or 900 mg for a period of 15 days, when steady-state concentrations were reached, the average RBC Cmax for the respective doses were measured to be 4950, 9610 and 14 000 g*h mL1, respectively.
Route of Elimination
62.6% of the voxelotor dose administered orally as well as its metabolites are found in the feces (with 33.3% as unchanged drug) and 35.5% in urine (with only 0.08% unchanged drug).
Volume of Distribution
The apparent volume of distribution of voxelotor in the central compartment is 338L and 72.2L in the plasma.
Clearance
The apparent oral clearance of voxelotor is approximately 6.7 L/h.
Voxeletor is heavily metabolized via 2 phases. Phase I consists of oxidation and reduction, while phase II consists of glucuronidation. Voseletor is oxidized mainly by CYP3A4, and to a lesser extent by CYP2C19, CYP2B6, and CYP2C9 hepatic cytochrome enzymes.
The plasma elimination half-life of voxelotor in sickle cell disease patients is about 35.5 hours, according to the FDA label. The mean half-life in the red blood cell is 60 days. The average plasma half-life of voxelotor was 50 hours in patients with sickle cell disease, compared with 6185 hours in healthy patients, in one clinical study.
Deoxygenated sickle hemoglobin (HbS) polymerization is the causal factor for sickle cell disease. The genetic mutation associated with this disease leads to the formation of abnormal, sickle shaped red blood cells that aggregate and block blood vessels throughout the body, causing vaso-occlusive crises. Voxelotor binds irreversibly with the Nterminal valine of the chain of hemoglobin, leading to an allosteric modification of Hb20, which increases the affinity for oxygen. Oxygenated HbS does not polymerize. By directly blocking HbS polymerization, voxelotor can successfully treat sickle cell disease by preventing the formation of abnormally shaped cells, which eventually cause lack of oxygenation and blood flow to organs.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Voxelotor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Voxelotor, including repackagers and relabelers. The FDA regulates Voxelotor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Voxelotor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Voxelotor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Voxelotor supplier is an individual or a company that provides Voxelotor active pharmaceutical ingredient (API) or Voxelotor finished formulations upon request. The Voxelotor suppliers may include Voxelotor API manufacturers, exporters, distributors and traders.
click here to find a list of Voxelotor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Voxelotor DMF (Drug Master File) is a document detailing the whole manufacturing process of Voxelotor active pharmaceutical ingredient (API) in detail. Different forms of Voxelotor DMFs exist exist since differing nations have different regulations, such as Voxelotor USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Voxelotor DMF submitted to regulatory agencies in the US is known as a USDMF. Voxelotor USDMF includes data on Voxelotor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Voxelotor USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Voxelotor suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Voxelotor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Voxelotor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Voxelotor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Voxelotor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Voxelotor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Voxelotor suppliers with NDC on PharmaCompass.
Voxelotor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Voxelotor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Voxelotor GMP manufacturer or Voxelotor GMP API supplier for your needs.
A Voxelotor CoA (Certificate of Analysis) is a formal document that attests to Voxelotor's compliance with Voxelotor specifications and serves as a tool for batch-level quality control.
Voxelotor CoA mostly includes findings from lab analyses of a specific batch. For each Voxelotor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Voxelotor may be tested according to a variety of international standards, such as European Pharmacopoeia (Voxelotor EP), Voxelotor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Voxelotor USP).
LOOKING FOR A SUPPLIER?